Fate Therapeutics to Present at the Jefferies 2019 Healthcare Conference
May 30 2019 - 4:05PM
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders, announced today that Scott Wolchko, President and Chief
Executive Officer, will present at the Jefferies 2019 Healthcare
Conference in New York on Thursday June 6, 2019 at 11:00 a.m. ET.
A live webcast of the presentation will be available through the
investor relations section of the Company's website at
www.fatetherapeutics.com. Following the live webcast, an archived
replay will be available on the Company's website.
About Fate Therapeutics, Inc. Fate
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to the development of first-in-class cellular
immunotherapies for cancer and immune disorders. The Company’s
immuno-oncology pipeline is comprised of universal, off-the-shelf
NK cell and T-cell product candidates that are mass produced using
its industry-leading induced pluripotent stem cell (iPSC) product
platform. In 2019, Fate Therapeutics initiated the first-ever
clinical trial in the United States of an iPSC-derived cell
product, and is developing this NK cell cancer immunotherapy,
FT500, for the treatment of patients with advanced solid tumors and
lymphomas that are resistant to checkpoint inhibitor therapy. The
Company is also developing FT516, an engineered iPSC-derived NK
cell product candidate incorporating a novel high-affinity,
non-cleavable 158V CD16 Fc receptor for enhanced binding to
monoclonal antibodies, and is advancing a highly-differentiated
pipeline of iPSC-derived chimeric antigen receptor (CAR) NK cell
and T-cell product candidates designed to simultaneously engage
multiple tumor-associated antigens for the treatment of hematologic
malignancies and solid tumors. The Company’s immuno-regulatory
pipeline includes ProTmune™, a pharmacologically-modulated, donor
cell graft that is currently being evaluated in a Phase 2 clinical
trial for the prevention of acute graft-versus-host disease (GvHD),
and an iPSC-derived myeloid-derived suppressor cell (MDSC)
immunotherapy for promoting immune tolerance in patients with
immune disorders. Fate Therapeutics is headquartered in San Diego,
CA. For more information, please
visit www.fatetherapeutics.com.
About Fate Therapeutics’ iPSC Product
PlatformThe Company’s proprietary induced pluripotent stem
cell (iPSC) product platform enables mass production of
off-the-shelf, engineered, homogeneous cell products that can be
administered in repeat doses to mediate more effective
pharmacologic activity, including in combination with cycles of
other cancer treatments. Human iPSCs possess the unique dual
properties of unlimited self-renewal and differentiation potential
into all cell types of the body. The Company’s first-of-kind
approach involves engineering human iPSCs in a one-time
modification event and selecting a single engineered iPSC for
maintenance as a clonal master iPSC line. Analogous to master cell
lines used to manufacture biopharmaceutical drug products such as
monoclonal antibodies, clonal master iPSC lines are a renewable
source for manufacturing cell therapy products which are
well-defined and uniform in composition, can be mass produced at
significant scale in a cost-effective manner, and can be delivered
off-the-shelf to treat many patients. As a result, the Company’s
platform is uniquely capable of overcoming numerous limitations
associated with the production of cell therapies using patient- or
donor-sourced cells, which is logistically complex and expensive
and is fraught with batch-to-batch and cell-to-cell variability
that can affect safety and efficacy. Fate Therapeutics’ iPSC
product platform is supported by an intellectual property portfolio
of over 100 issued patents and 100 pending patent applications.
Contact: Christina Tartaglia Stern Investor
Relations, Inc. 212.362.1200 christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Sep 2023 to Sep 2024